A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...

For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...

Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

According to a new report from Big Chalk Analytics, GLP-1 users have cut $6.5 billion from U.S. grocery spend.

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also ...

A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

For weight loss, weight management, and overall wellness, focus on eating healthy foods, like high-protein meals, legumes, ...

Men were three times more likely than women to say GLP-1s boosted their confidence and two times more likely to say they were going on more dates. They also reported higher libido, more matches and ...